GTx Inc. (NASDAQ:GTXI) major shareholder Peak Foundation Pyramid purchased 7,716,049 shares of the firm’s stock in a transaction that occurred on Friday, October 14th. The stock was bought at an average price of $0.81 per share, for a total transaction of $6,249,999.69. Following the transaction, the insider now directly owns 38,249,528 shares of the company’s stock, valued at approximately $30,982,117.68. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

GTx Inc. (NASDAQ:GTXI) traded up 0.9674% on Monday, reaching $0.9289. The company’s stock had a trading volume of 162,071 shares. The firm has a market cap of $131.82 million, a PE ratio of 5.5958 and a beta of 2.35. GTx Inc. has a 52-week low of $0.29 and a 52-week high of $1.15. The stock’s 50 day moving average price is $0.74 and its 200 day moving average price is $0.66.

GTx (NASDAQ:GTXI) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts expect that GTx Inc. will post ($0.12) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

An institutional investor recently raised its position in GTx stock. BVF Inc. IL boosted its position in shares of GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx makes up approximately 1.4% of BVF Inc. IL’s portfolio, making the stock its 21st largest position. BVF Inc. IL owned approximately 8.12% of GTx worth $5,756,000 as of its most recent SEC filing. 10.78% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts recently commented on the company. Jefferies Group restated a “hold” rating and issued a $1.00 price target on shares of GTx in a research report on Friday, September 9th. Zacks Investment Research upgraded GTx from a “sell” rating to a “hold” rating in a research report on Tuesday, July 12th.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

5 Day Chart for NASDAQ:GTXI

Receive News & Stock Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related stocks with our FREE daily email newsletter.